New Delhi, Sep 27, (UNI) Lupin Ltd has acquired Rubamin Laboratories Ltd (RLL), a part of the Rubamin group, for an undisclosed amount.
Rubamin Laboratories makes raw materials for bulk drugs on a contract manufacturing basis.
It has capabilities to participate in the value chain from drug development to commercial production of advanced intermediates for APIs.
''We are delighted at this acquisition. It enables us to step up our strategic initiative in the CRAMS segment. We have a proven track record of achieving global position in every therapy that we have entered at intermediate and API level,'' Lupin Chairman Dr Desh Bandhu Gupta said in a statement.